ACE (angiotension-converting enzyme) Inhibitor: A drug that lowers blood pressure by interfering with the breakdown of a protein-like substance involved in blood pressure regulation.

Angina pectoris: Chest pain that occurs when diseased blood vessels restrict blood flow to the heart.

Angioplasty: A non-surgical technique for opening partially closed or blocked arteries by temporarily inflating a tiny balloon inside the artery.

Artery: A vessel that carries oxygen-rich blood from the heart to the body.

Arthroscopy : A surgical technique whereby a tube-like instrument is inserted into a joint to inspect, diagnose and repair tissues.

Beta blocker: A drug that lowers blood pressure by limiting the action of adrenaline (epinephrine), a hormone that increases blood pressure.

Cartilage : Firm, rubbery tissue that cushions bones at joints. A more flexible kind of cartilage connects muscles with bones and makes up other parts of the body, such as the larynx and the outside parts of the ears.

Degenerative disc disease: A spinal condition caused by the break down of the intervertebral discs. The condition is usually age-related or caused by injury. The discs lose their flexibility and ability to cushion the spine. Since there is poor blood supply to the discs, injury is extremely difficult to treat.

Diuretic: A drug that lowers blood pressure by stimulating fluid loss and promoting the production of urine.

Heart attack: Death of, or damage to, a region of heart muscle due to an insufficient blood supply.

Congestive heart failure (CHF): A condition in which the heart cannot pump all the blood returning to it, leading to a back-up of blood in vessels and accumulation of fluid in body tissues, including the lungs.

Coronary artery disease (CAD): A narrowing of the inside diameter of arteries that supply the heart with blood which interferes with the blood supply to the heart muscle. .

Good manufacturing process (GMP): Extensive quality assurance, accountability, and sterile conditions required for production of drugs for human usage.

Graft : Healthy skin, bone, or other tissue taken from one part of the body to replace diseased or injured tissue removed from another part of the body.

Infarction: Heart attack.

Mesenchymal stem cells (MSCs): Cells found in the bone marrow of adults, capable of differentiating into bone, heart muscle, neurons and other organ tissues.

Mesenchymal precursor cells (MPCs): Cells capable of giving rise to MSCs. They are primarily found in the bone marrow, dental pulp, fat and skin.

Monoclonal antibody: An antibody which specifically binds to the compound of interest.

Myocardial regeneration: The ability of heart muscle cells to divide and extend into the damaged region of the heart in a finger-like fashion. Mesoblast has discovered that this process is dependent on sufficient oxygen and nutrients.

Osteoarthritis: A type of arthritis caused by inflammation, break down, and eventual loss of cartilage in the joints. Also known as degenerative arthritis.

Ulcer: A region of damage to skin or an internal mucous surface that results in death of the tissue.

The Technology

 

Last Share Price

August 26 2010- Preliminary 2010 Annual Report

August 26 2010 - Mesoblast Financial Year End Results; Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy

23 August 2010 - EGM documents - Letter from the Chairman, Notice of Meeting, Independent Expert Report.

16 August - Mesoblast on track for phase 3 bone marrow transplant trial following positive meeting with FDA

21 July - Mesoblast receives TGA regulatory approval to commercially manufacture adult stem cell products

12 July - Phase 3 meeting scheduled with FDA following positive results of bone marrow regeneration trial

28 May - Mesoblast featured at ASX Singapore conference highlighting emerging market leaders

19 May - United States FDA Clears Phase 2 Trial for Cervical Spinal Fusion

16 August 2010 - Southern Cross Equities research - Phase III getting ready for takeoff

23 July 2010 - Southern Cross Equities Research – Big Pharma will be watching

21 July 2010 - Southern Cross Equities Research – The clinical endgame nears

17 May 2010 - Southern Cross Equities Research – Capitalising the Stem Cell Opportunity

14 May 2010 - Bioshares

26 February - RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters

July 2009 - Chairman’s Letter

May 2009 - Chairman’s Letter

May 2008 - Issue Nine